ImmunoPrecise Antibodies Ltd. Files AGM Voting Results
Ticker: HYFT · Form: 6-K · Filed: Nov 18, 2024 · CIK: 1715925
Sentiment: neutral
Topics: agm, voting-results, filing-update
TL;DR
IPA filed their AGM voting results, incorporated into S-8 and F-3 filings.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on November 18, 2024, reporting voting results from their AGM held on November 15, 2024. The filing incorporates these results by reference into existing registration statements on Form S-8 and Form F-3.
Why It Matters
This filing provides shareholders with the official results of the Annual General Meeting, indicating the outcome of shareholder votes on key corporate matters.
Risk Assessment
Risk Level: low — This is a routine filing reporting on voting results from an annual general meeting, not indicating new financial or operational risks.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- November 15, 2024 (date) — Date of AGM and Voting Results
- November 18, 2024 (date) — Filing Date of Form 6-K
- Form S-8 (document) — Registration Statement
- Form F-3 (document) — Registration Statement
FAQ
What type of report is ImmunoPrecise Antibodies Ltd. filing?
ImmunoPrecise Antibodies Ltd. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
When were the voting results reported in this filing conducted?
The voting results reported are from the Annual General Meeting held on November 15, 2024.
What is the filing date of this Form 6-K?
This Form 6-K was filed as of November 18, 2024.
Into which registration statements are the exhibits incorporated by reference?
Exhibit 99.1 is incorporated by reference into Registration Statement on Form S-8 (File No. 333-256730) and Registration Statements on Form F-3 (File Nos. 333-273197 and 333-281312).
What is the principal executive office address of ImmunoPrecise Antibodies Ltd.?
The principal executive office is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
Filing Stats: 189 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-11-15 17:39:52
Filing Documents
- agm_nov_2024_voting_resu.htm (6-K) — 23KB
- ipa-ex99_1.htm (EX-99.1) — 29KB
- 0000950170-24-127706.txt ( ) — 53KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: November 15, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer